Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis.
Han W, Wang L, Li C, Chen J, Zhang W, Wang X, Pang Q, Zhao Y, Sun X, Zhang K, Li G, Li L, Qiao X, Liu M, Wang Y, Deng L, Wang W, Bi N, Zhang T, Deng W, Ni W, Chang X, Zhou Z, Liang J, Feng Q, Wang L, Chen D, Lv J, Zhu S, Han C, Xiao Z. Han W, et al. Among authors: zhang w, zhang t, zhang k. Ther Adv Med Oncol. 2022 Oct 28;14:17588359221131526. doi: 10.1177/17588359221131526. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36324733 Free PMC article.
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
Wang Y, Zhang T, Wang J, Zhou Z, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Ma X, Xue Q, Wang J, Wang Z, Bi N. Wang Y, et al. Among authors: zhang t. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):590-600. doi: 10.1016/j.ijrobp.2022.12.042. Epub 2023 Jan 7. Int J Radiat Oncol Biol Phys. 2023. PMID: 36623605
Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
Yu N, Cheng G, Li J, Liang J, Zhang T, Deng L, Liu W, Wang J, Zhai Y, Wang W, Xiao Z, Zhou Z, Chen D, Feng Q, Bi N, Wang X. Yu N, et al. Among authors: zhang t. Curr Cancer Drug Targets. 2023;23(8):653-662. doi: 10.2174/1568009623666230315145937. Curr Cancer Drug Targets. 2023. PMID: 36924100 Clinical Trial.
Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang X, Han W, Zhang W, Wang X, Ge X, Lin Y, Zhou H, Hu M, Wang W, Liu K, Lu J, Qie S, Zhang J, Deng W, Wang L, Han C, Li M, Zhang K, Li L, Wang Q, Shi H, Yu Z, Zhao Y, Sun X, Shi Y, Pang Q, Zhou Z, Liang J, Chen D, Feng Q, Bi N, Zhang T, Deng L, Wang W, Liu W, Wang J, Zhai Y, Wang J, Chen W, Chen J, Xiao Z; Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG). Wang X, et al. Among authors: zhang w, zhang t, zhang j, zhang k. JAMA Netw Open. 2023 May 1;6(5):e2312625. doi: 10.1001/jamanetworkopen.2023.12625. JAMA Netw Open. 2023. PMID: 37195667 Free PMC article. Clinical Trial.
Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
Yang Y, Wang J, Zhang T, Zhou Z, Wang Y, Jiang Y, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Wang W, Xue Q, Wang J, Li YX, Bi N. Yang Y, et al. Among authors: zhang t. Front Immunol. 2023 Nov 24;14:1281888. doi: 10.3389/fimmu.2023.1281888. eCollection 2023. Front Immunol. 2023. PMID: 38077319 Free PMC article.
Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
Yang Y, Wang J, Wang J, Zhao X, Zhang T, Yang Y, Pang J, Ou Q, Wu L, Xu X, Xu K, Zhao J, Bai N, Yang P, Wang S, Wang L, Bi N. Yang Y, et al. Among authors: zhang t. Cancer Lett. 2024 Feb 1;582:216569. doi: 10.1016/j.canlet.2023.216569. Epub 2023 Dec 13. Cancer Lett. 2024. PMID: 38101608
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Wang Y, et al. Among authors: zhang t. Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023. Front Immunol. 2024. PMID: 38288117 Free PMC article.
35,396 results
You have reached the last available page of results. Please see the User Guide for more information.